CS
SGMO

Credit Suisse’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Credit Suisse’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-10,000
Closed -$120K – 4523
2021
Q2 		$120K Hold
10,000
– – ﹤0.01% 4353
2021
Q1 		$125K Buy
+10,000
New +$135K ﹤0.01% 4176
2015
Q1 		– Sell
-120,700
Closed -$1.84M – 4558
2014
Q4 		$1.84M Hold
120,700
– – ﹤0.01% 2605
2014
Q3 		$1.3M Buy
+120,700
New +$1.58M ﹤0.01% 2829

Other funds holding SGMO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Credit Suisse's SGMO Position: Q4 2023 in Review

Credit Suisse sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q4 2023, closing a stake of 3,700,000 shares — an estimated $2.22M sold.

Credit Suisse first reported a position in SGMO in Q2 2013 and held it in 42 quarters. The position peaked at $53.2M in Q4 2020. 130 funds tracked by Wall St. Rank hold SGMO as of Q4 2023.

  • Credit Suisse reported no remaining SANGAMO THERAPEUTICS INC position as of Q4 2023 after selling out during the quarter.
  • Credit Suisse sold 3,700,000 SANGAMO THERAPEUTICS INC shares in Q4 2023, an estimated $2.22M.
  • Credit Suisse first reported a position in SANGAMO THERAPEUTICS INC in Q2 2013 and held it in 42 quarters.
  • Credit Suisse's SANGAMO THERAPEUTICS INC position peaked at $53.2M in Q4 2020.
  • 130 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q4 2023.

Based on Credit Suisse's 13F filing for Q4 2023, filed 8 Feb 2024.